-
2
-
-
0032970737
-
Chlamydia pneumoniae and atherosclerosis
-
Wong Y-K, Gallagher PJ, Ward ME: Chlamydia pneumoniae and atherosclerosis. Heart 1999;81:232-238.
-
(1999)
Heart
, vol.81
, pp. 232-238
-
-
Wong, Y.-K.1
Gallagher, P.J.2
Ward, M.E.3
-
3
-
-
0033613066
-
Chlamydia pneumoniae infection of vascular smooth and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis
-
Dechend R, Maass M, Geiffers J, et al: Chlamydia pneumoniae infection of vascular smooth and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999;100:1369-1373.
-
(1999)
Circulation
, vol.100
, pp. 1369-1373
-
-
Dechend, R.1
Maass, M.2
Geiffers, J.3
-
4
-
-
19644362702
-
Effects of antibiotic therapy on outcomes of patients with coronary artery disease
-
Andraws R, Berger JS, Brown DL: Effects of antibiotic therapy on outcomes of patients with coronary artery disease. JAMA 2005;293:2641-2647.
-
(2005)
JAMA
, vol.293
, pp. 2641-2647
-
-
Andraws, R.1
Berger, J.S.2
Brown, D.L.3
-
5
-
-
17244372856
-
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome
-
Cannon CP, Braunwald E, McCabe CH, et al: Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646-1654.
-
(2005)
N Engl J Med
, vol.352
, pp. 1646-1654
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
6
-
-
0037426067
-
Effects of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: A randomized controlled trial
-
Cercek B, Shah PK, Noc M, et al: Effects of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial. Lancet 2003;361:809-813.
-
(2003)
Lancet
, vol.361
, pp. 809-813
-
-
Cercek, B.1
Shah, P.K.2
Noc, M.3
-
7
-
-
20244366215
-
Azithromycin for the secondary prevention of coronary events
-
Grayston JT, Kronmal R, Jackson LA, et al: Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637-1645.
-
(2005)
N Engl J Med
, vol.352
, pp. 1637-1645
-
-
Grayston, J.T.1
Kronmal, R.2
Jackson, L.A.3
-
8
-
-
30344454405
-
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
-
Jesperson CM, Als-Nielsen B, Damgaard M, et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-27.
-
(2006)
BMJ
, vol.332
, pp. 22-27
-
-
Jesperson, C.M.1
Als-Nielsen, B.2
Damgaard, M.3
-
9
-
-
55249099789
-
Clarithromycin for 2 weeks for stable coronary heart disease:6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease
-
Gluud C, Als-Nielsen B, Damgaard M, et al: Clarithromycin for 2 weeks for stable coronary heart disease:6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;1 111:280-287.
-
(2008)
Cardiology
, vol.1
, Issue.111
, pp. 280-287
-
-
Gluud, C.1
Als-Nielsen, B.2
Damgaard, M.3
-
10
-
-
3142574652
-
Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL
-
Mizunoe S, Kadota J, Tokimatsu I, et al: Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004;4:1201-1207.
-
(2004)
Int Immunopharmacol
, vol.4
, pp. 1201-1207
-
-
Mizunoe, S.1
Kadota, J.2
Tokimatsu, I.3
-
11
-
-
34447627450
-
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials
-
Alsheik-Ali A, Maddukuri PV, Han H, et al: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-418.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 409-418
-
-
Alsheik-Ali, A.1
Maddukuri, P.V.2
Han, H.3
-
12
-
-
38449120272
-
The association between statins and cancer incidence in a veterans' population
-
Farwell WR, Scranton RE, Lawler EV, et al: The association between statins and cancer incidence in a veterans' population. J Natl Cancer Inst 2008;100:134-139.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 134-139
-
-
Farwell, W.R.1
Scranton, R.E.2
Lawler, E.V.3
-
13
-
-
34447645500
-
Means and ends of statin and low-density lipoprotein cholesterol lowering
-
LaRossa JC: Means and ends of statin and low-density lipoprotein cholesterol lowering. J Am Coll Cardiol 2007;50:419-420.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 419-420
-
-
LaRossa, J.C.1
-
14
-
-
34447635241
-
Low-density lipoprotein reduction and cancer
-
DeMaria AN, Ben Yahuda O: Low-density lipoprotein reduction and cancer. J Am Coll Cardiol 2007;50:421-422.
-
(2007)
J Am Coll Cardiol
, vol.50
, pp. 421-422
-
-
DeMaria, A.N.1
Ben Yahuda, O.2
|